The Hux Cancer Center has maintained a comprehensive tumor registry since 1963. This is the longest continuously active tumor registry in the Wabash Valley. The tumor registry provides information regarding the types and outcomes of cancer in the Wabash Valley and is linked to the Indiana State Board of Health Tumor Registry.

Current Clinical Trials

GI TUMORS

ANAL CANCER
RTOG 98-11
A PHASE Ill RANDOMIZED STUDY OF 5-FLUOROURACIL, MITOMYCIN-C AND RADIOTHERAPY VERSUS 5-FLUOROURACIL, CISPLATIN AND RADIOTHERAPY IN CARCINOMA OF THE ANAL CANAL

STOMACH
RTOG 99-04
A PHASE II TRIAL OF PREOPERATIVE CHEMOTHERAPY AND CHEMO- RADIOTHERAPY FOR POTENTIALLY RESECTABLE ADENOCARCINOMA OF THE STOMACH

COLON
PTK787/ZK 222584
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III STUDY IN PATIENTS WITH METASTATIC ADENOCARCINOMA OF THE COLON OR RECTUM WHO ARE RECEIVING FIRST-LINE CHEMOTHERAPY WITH OXALIPLATIN/5-FLUOROURACIL/LEUCOVORIN AND PTK787/ZK 222584 OR PLACEBO

ESOPHAGUS
RTOG E-0113
NON-OPERATIVE THERAPY OF LOCAL-REGIONAL CARCINOMA OF THE ESOPHAGUS: A RANDOMIZED PHASE II STUDY OF TWO PACLITAXEL-BASED CHEMORADIOTHERAPY REGIMENS

HEAD & NECK CANCER
RTOG 95-12
A RANDOMIZED STUDY OF HYPERFRACTIONATION VERSUS CONVENTIONAL FRACTIONATION IN T2 SQUAMOUS CELL CARCINOMA OF THE VOCAL CORD

GU CANCER

PROSTATE
RTOG 99-10
A PHASE III TRIAL TO EVALUATE THE DURATION OF NEOADJUVANT TOTAL ANDROGEN SUPPRESSION (TAS) AND RADIATION THERAPY (RT) IN INTERMEDIATE-RISK PROSTATE CANCER

RTOG 99-02
A PHASE III PROTOCOL OF ANDROGEN SUPPRESSION (AS) AND RADIATION THERAPY (RT) VS AS AND RT FOLLOWED BY CHEMOTHERAPY WITH PACLITAXEL,

ESTRAMUSTINE, AND ETOPOSIDE (TEE) FOR LOCALIZED, HIGH-RISK, PROSTATE CANCER.

RTOG P-0014
A PHASE III RANDOMIZED STUDY OF PATIENTS WITH HIGH RISK, HORMONE-NAIVE PROSTATE CANCER: ANDROGEN BLOCKADE WITH 4 CYCLES OF IMMEDIATE CHEMOTHERAPY VERSUS ANDROGEN BLOCKADE WITH DELAYED CHEMOTHERAPY

LUNG CANCER

LCCC 2012
A RANDOMIZED PHASE II TRIAL TO OUTLINE THE EFFICACY OF GEMCITABINE CONTAINING REGIMENS (GEMZAR/CARBOPLATIN AND GEMZAR/PACLITAXEL) WHEN USED AS PREOPERATIVE CHEMOTHERAPY IN PATIENTS WITH STAGE I AND II NSCLC

RTOG 0214
A PHASE III COMPARISON OF PROPHYLACTIC CRANIAL IRRADIATION VERSUS OBSERVATION IN PATIENTS WITH LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER

RTOG L-0127
PHASE III CHEMOPREVENTION TRIAL OF SELENIUM SUPPLEMENTATION IN PERSONS WITH RESECTED STAGE I NON-SMALL CELL LUNG CANCER

RTOG L-0117
A PHASE I/II DOSE INTENSIFICATION STUDY USING THREE DIMENSIONAL CONFORMAL RADIATION THERAPY AND CONCURRENT CHEMOTHERAPY FOR PATIENTS WITH INOPERABLE, NON-SMALL CELL LUNG CANCER

RTOG 0212
A PHASE II/III RANDOMIZED TRIAL OF TWO DOSES (PHASE III-STANDARD VS. HIGH) AND TWO HIGH DOSE SCHEDULES (PHASE II-ONCE VS. TWICE DAILY) FOR DELIVERING PROPHYLACTIC CRANIAL IRRADIATION FOR PATIENTS WITH LIMITED DISEASE SMALL CELL LUNG CANCER

(S.C.) LUN 52
A RANDOMIZED PHASE III COMPARISON OF WEEKLY DOCETAXEL VERSUS WEEKLY DOCETAXEL/GEMCITABINE IN THE TREATMENT OF ELDERLY OR POOR PERFORMANCE STATUS PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER

(S.C.) LUN 54
PHASE III RANDOMIZED STUDY OF PACLITAXEL, CARBOPLTIN AND GEMCITABINE VERSUS GEMCITABINE AND VINORELBINE AS FIRST-LINE CHEMOTHERAPY FOR STAGE IIIB AND IV NON-SMALL CELL LUNG CANCER

RTOG 0123
A PHASE II RANDOMIZED TRIAL WITH CAPTOPRIL IN PATIENT WHO HAVE RECEIVED RADIATION THERAPY +/- CHEMOTHERAPY FOR STAGE II-IIIB NON-SMALL CELL LUNG CANCER, STAGE I CENTRAL NON-SMALL CELL LUNG CANCER, OR LIMITED-STAGE SMALL CELL LUNG CANCER

LUN 66
PHASE II TRIAL OF WEEKLY TOPOTECAN IN THE SECOND-LINE TREATMENT OF SMALL CELL LUNG CANCER

HOG-LUN01-24
A PHASE III TRIAL OF CISPLATIN/ETOPOSIDE/RADIOTHERAPY WITH OR WITHOUT CONSOLIDATION DOCETAXEL IN PATIENTS WITH INOPERABLE LOCALLY ADVANCED STAGE III NON-SMALL CELL LUNG CANCER (NSCLC).

CNS TUMORS

RTOG 0212
A PHASE II/IIl RANDOMIZED TRIAL OF TWO DOSE SCHEDULES FOR DELIVERING PROPHLACTIC CRANIAL IRRADIATION FOR PATIENTS WITH LIMITED DISEASE SMALL CELL LUNG CANCER

RTOG 98-13
A PHASE I/III RANDOMIZED STUDY OF RADIATION THERAPY AND TEMOZOLOMIDE VERSUS RADIATION THERAPY AND BCNU FOR ANAPLASTIC ASTROCYTOMA

RTOG BR-0118
A PHASE III STUDY OF CONVENTIONAL RADIATION THERAPY PLUS THALIDOMIDE (NSC#66847) VERSUS CONVENTIONAL RADIATION THERAPY FOR MULTIPLE BRAIN METASTASES.

RTOG 0211
A PHASE I/II STUDY OF AN ORAL EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR (EGFR-TKI), ZD 1839 (IRESSA@), [NSC#715055] WITH RADIATION THERAPY IN GLIOBLASTOMA MULTIFORME.

BREAST CANCER

UNIVERSITY OF WASHINGTON PROTOCOL 02-01
A PHASE III RANDOMIZED STUDY OF THREE DIFFERENT DOSES OF WEEKLY DOCETAXEL AS FIRST-LINE TREATMENT OF METASTATIC BREAST CANCER

CZOL44E US32
AN OPEN-LABEL, RANDOMIZED, MULTICENTER STUDY TO EVALUATE THE USE OF ZOLEDRONIC ACID IN THE PREVENTION OF CANCER TREATMENT-RELATED BONE LOSS IN POSTMENOPAUSAL WOMEN WITH ER+ AND/OR PR+ BREAST CANCER RECEIVING LETROZOLE AS ADJUVANT THERAPY

RTOG 98-04/CALGB 49801
PHASE Ill TRIAL OF TAMOXIFEN ALONE VS. TAMOXIFEN PLUS RT FOR GOOD RISK DUCT CARCINOMA IN-SITU (DCIS) OF THE FEMALE BREAST

HEMATOLOGY

(S.C.) LYM 21
A PHASE II TRIAL OF RITUXIMAB/FLUDARABINE (OR SINGLE-AGENT RITUXIMAB) FOLLOWED BY CAMPATH-1H IN THE FIRST-LINE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

RTOG 0227
PHASE I/II STUDY OF PRE-IRRADIATION CHEMOTHERAPY WITH METHOTRETATE, RITUXIMAB, AND TEMOZOLOMIDE AND POST-IRRADIATION TEMOZOLOMIDE FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

GYN CANCER

RTOG C-0128
A PHASE I/II STUDY OF COX-2 INHIBITOR, CELEBREX* (CELECOXIB), AND CHEMORADIATION IN PATIENTS WITH LOCALLY ADVANCED CERVICAL CANCER

RTOG C-0116
A TWO PART PHASE I/II STUDY OF EXTENDED FIELD EXTERNAL IRRADIATION AND INTRACAVITARY BRACHYTHERAPY COMBINED WITH CHEMOTHERAPY (WEEKLY CISPLATIN - ARM I) AND AMIFOSTINE (WEEKLY CISPLATIN AND AMIFOSTINE - ARM II) IN CARCINOMA OF THE CERVIX WITH POSITIVE PARAAORTIC OR HIGH COMMON ILIAC LYMPH NODES

[< top >]